Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient

We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir loo...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in infectious diseases 2023-10, Vol.2023, p.8865265-5
Main Authors: Bigirimana, Ferdinand, Van den Wijngaert, Sigi, Fosso, Christelle, Stoffels, Karolien, Martin, Charlotte, Maillart, Evelyne, Clevenbergh, Philippe
Format: Article
Language:English
Subjects:
Anti-HIV agents
Antiviral agents
Case Report
Cholesterol
Chronic kidney failure
Darunavir
Drug dosages
Enzymes
Glucose
Hemodialysis
HIV (Viruses)
HIV infection
Kidney transplants
Kidneys
Multidrug resistant organisms
Patients
Peritoneal dialysis
Pharmacokinetics
Phosphatase
Reverse transcriptase inhibitors
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.
ISSN:2090-6625
2090-6633
DOI:10.1155/2023/8865265